B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Clinical trials for B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 explained in plain language.
Never miss a new study
Get alerted when new B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 trials appear
Sign up with your email to follow new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a common nutrient shield young cancer patients from Chemo's toxic side effects?
Disease control Recruiting nowThis study aims to see if adding a nutrient supplement called levocarnitine to standard chemotherapy can protect the liver in adolescents and young adults (ages 15-39) being treated for leukemia or lymphoma. A key chemotherapy drug, asparaginase, often causes severe liver damage …
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Targeted drug combo offers hope for Tough-to-Treat leukemia
Disease control Recruiting nowThis study is testing a combination of a targeted cancer drug (inotuzumab ozogamicin), low-intensity chemotherapy, and an immunotherapy drug (blinatumomab) for adults with acute lymphoblastic leukemia (ALL). It focuses on older patients (60+) or younger patients who are too frail…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Custom immune cells fight blood cancers after transplant
Disease control Recruiting nowThis study tests a personalized immune cell therapy for patients with blood cancers like leukemia, lymphoma, and myeloma. After receiving chemotherapy and a cord blood transplant, patients get infusions of natural killer (NK) cells—immune cells that may kill remaining cancer cell…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Scientists test new pill cocktail in fight against tough leukemia
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a new combination of oral pills (venetoclax and dasatinib) for adults with a specific, aggressive type of blood cancer called Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) or mixed phenotype acute…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New drug combo aims to control aggressive blood cancer
Disease control Recruiting nowThis study is testing a combination of chemotherapy drugs and a targeted therapy called ponatinib for adults newly diagnosed with a fast-growing type of blood cancer. The goal is to see if this combination is safe and effective at putting the cancer into deep remission and preven…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Major cancer trial tests new drug combo to fight aggressive leukemia
Disease control Recruiting nowThis study is for adults newly diagnosed with a specific, aggressive type of blood cancer called BCR-ABL-positive acute lymphoblastic leukemia (ALL). It aims to see if adding a newer immunotherapy drug called blinatumomab to the standard treatment (steroids, a targeted pill, and …
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC